received the most attention, particularly the NS3 serine protease where potent inhibitors have been described. Crystal structures of key replicative enzymes, NS3 protease, NS3 helicase, NS5B polymerase and now full-length NS3 protease-helicase, are available. More recently, targeting the host sys-tem has become of interest, particularly inhibitors of inosine monophosphate dehydrogenase. Research aimed at novel treatments for HCV disease is gathering pace and very recent developments in cell-based assay systems can only hasten the discovery of improved therapies.
Hepatitis C virus (HCV) has infected an estimated 170 million people worldwide, leading to a major health crisis as a result of the disease (Cuthbert, 1994; Houghton, 1996; Mast & Alter, 1993) . Indeed, during the next few years the number of deaths from HCV-related liver disease and hepatocellular carcinoma may overtake those caused by AIDS (Cohen, 1999a) . Egypt is the hardest hit country in the world, with 24% of the population estimated to be carrying the virus (Cohen, 1999b) , whereas in the USA the prevalence of chronic infections has recently been determined at around 1.8% (2.7 million persons) (Alter et al., 1999) . HCV infections become chronic in about 50% of cases (Cuthbert, 1994; Houghton, 1996) . Of these, about 20% develop liver cirrhosis that can lead to liver failure, including hepatocellular carcinoma. Recent reviews in this area include future directions, targets and progress (Bartenschlager, 1997; Gish, 1999; Le et al., 1998; Poordad & Gish, 1999; Shoemaker & Thaisrivongs, 1999; Walker, 1999) . This review will briefly summarize treatments currently available and will focus on a discussion of approaches being taken towards the discovery and development of novel therapies for the treatment of HCV disease.
Current treatments
Current treatment for chronic HCV infection requires interferon α (IFN-α) (Berenguer & Wright, 1998; Hoofnagle & Di Bisceglie, 1997; Rosen & Gretch, 1999) . Only about 40% of patients respond to IFN-α treatment and, after cessation of therapy, about 70% of responders relapse. Early monitoring of viral load could help success rates (Neumann et al., 1998) . Recent results have shown that a combination of ribavirin, a broad spectrum antiviral (Sidwell et al., 1972) , with IFN-α is significantly more effective than administration of IFN-α alone (Davis et al., 1998; McHutchison et al., 1998) . Ribavirin and its postulated mode of action as an inhibitor of inosine monophosphate dehydrogenase (IMPDH) will be discussed in more detail later. Improvements in dosing have been achieved with pegylated-IFN, resulting in only once weekly doses (Heatcote et al., 1999; Shiffman et al., 1999; Bailon & Palleroni, 1997) . This product, which is in Phase III clinical trials, consists of a 40 kDa polyethylene glycol (PEG) strand attached to the recombinant IFN. This increases its half-life from 7-10 h to approximately 100 h. Furthermore, combination of pegylated-IFN with ribavirin shows promising antiviral activity in patients with chronic HCV (Sulkowski et al., 1999) .
Cellular systems and animal models
The lack of a reliable and efficient cell culture system has hampered studies on virus replication. Understanding of viral pathogenesis and development of potential drug candidates has been hindered by slow progress in the development of an animal model that can support replicating virus (Schinazi et al., 1999) . Chimpanzees are currently the only non-human animal model for reproducible propagation of Introduction HCV. During efforts to identify a more suitable species for drug candidate evaluation, a chimeric mouse model (trimera mouse) has been described (Galun et al., 1995) .
Extensive research into remedying the lack of a cellular replication model has resulted in cellular systems using normal human hepatocytes (Fournier et al., 1998) , but the recent development of a subgenomic RNA replication system (Lohmann et al., 1999a) may be more amenable to drug discovery. The subgenomic RNA 'replicon' encodes the necessary proteins and carries the essential cis-acting signals for it to undergo replication, but no virus particles can be produced because the structural protein-coding region has been deleted. However, because all of the genes necessary for replication are present, this system could be used for the evaluation of drug candidates targeted at the essential non-structural gene products. Additionally, using the replicon cellular assay as a primary screen could facilitate the search for new lead compounds.
Virus targets
The HCV genome HCV comprises a positive-strand RNA genome enclosed in a nucleocapsid and lipid envelope (Bartenschlager, 1997) . The genome consists of approximately 9600 nucleotides carrying a single open reading frame (ORF), which encodes a polyprotein of around 3000 amino acids. This polyprotein is cleaved both co-and post-translationally into the functional viral proteins, from the N to the C terminus: C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B ( Figure 1 ; for a detailed review see Bartenschlager, 1997) . The ORF is flanked by 5′ and 3′ untranslated regions (UTRs), which are important for translation and replication. Putative essential HCV replication proteins and genomic secondary structures, such as the internal ribosome entry site (IRES) and the 3′-UTR, as targets for anti-HCV therapy have been recently reviewed (Bartenschlager, 1997; Clarke, 1997) . Functions for most of the viral proteins have been described. The C protein interacts with the virus RNA and forms the nucleocapsid (Matsumoto et al., 1996; Santolini et al., 1994) . E1 and E2 are heavily glycosylated transmembrane envelope proteins that are the major glycoproteins embedded into the lipid envelope (Dubuisson et al., 1994; Ralston et al., 1993; Selby et al., 1994) . Light has recently been shed on possible mechanisms of IFN-α resistance by a report describing the discovery that the HCV envelope protein E2 contains a sequence identical to IFN-inducible protein kinase PKR phosphorylation sites and translation initiation factor elF2α (Taylor et al., 1999) . E2 inhibited the kinase activity of PKR and blocked its inhibitory effect on protein synthesis and cell growth. Further elucidation of the interaction between E2 and PKR could lead to improved therapies. A short hydrophobic peptide (p7) separates the structural from the non-structural proteins. The function of the p7 protein in the virus life-cycle is unknown. The non-structural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B are responsible for polyprotein processing and virus replication. The roles of these proteins and progress of drug discovery against these targets will be described in detail as they represent the most published routes to antiviral therapy. Gene products: background and drug discovery progress NS2/3 protease Host signal peptidases are responsible for cleavages in the structural to NS2 region of the HCV polyprotein (Hijikata et al., 1993; Santolini et al., 1994) . The non-structural proteins are produced from the polyprotein by the action of two HCV-encoded proteases. NS3/4A is a chymotrypsinlike serine protease located in the N-terminal one-third of NS3 protease (see below) and a second virus-encoded protease is responsible for cleavage at the two-thirds site (Grakoui et al., 1993; Hijikata et al., 1993) . This NS2/3 protease encompasses most of the NS2 region and part of the NS3 polypeptide. No homology has been found with known proteases, but it has been proposed to be either: (i) a metalloprotease, on the basis of the observation that its proteolytic activity is inhibited by EDTA and stimulated by zinc (Hijikata et al., 1993; Pieroni et al., 1997) ; or (ii) a cysteine protease, supported by site-directed mutagenesis experiments showing that two single point mutations within the NS2 domain, H952A or C993A, abolished NS2/3 proteolytic activity (Hijikata et al., 1993 , Wu et al., 1998 . The availability of an in vitro assay system (Pieroni et al., 1997) will provide the means to screen for inhibitors of this protease.
NS3/4A protease/helicase/NTPase
The NS3 protein of HCV possesses three activities likely to be essential for virus replication. These are a serine pro- 
NS3 protease
The most intensely studied and therefore best understood target for HCV antiviral therapy is the NS3 protease. The activity of this protease resides in the N-terminus of the NS3 domain and requires the 54 amino acid cofactor NS4A for maximum cleavage activity (Bartenschlager, 1997; Bartenschlager et al., 1993 Bartenschlager et al., , 1995 Overton et al., 1995) . NS3 mediates cleavage of NS3-4A, NS4A-4B, NS4B-5A and NS5A-5B and is therefore an excellent target for the inhibition of viral replication. The C-terminus of NS3 is responsible for a NTPase/helicase activity, discussed below. The NS3 protease enzyme represents the most advanced target in inhibition of the HCV gene products to date and has been recently reviewed from the structural point of view (Kwong et al., 1998a,b) . Here we review both substrate and non-substrate based inhibitors of this protease.
Substrate-based inhibitors. The NS3 protease has been shown to be a chymotrypsin-like serine protease (Hahm et al., 1995) . Typically, serine proteases of this type can be inhibited by inhibitors derived from the cleaved substrate wherein the scissile amide bond is replaced by an electrophile, which interacts with the catalytic serine (Edwards & Bernstein, 1994) . This approach has been used by several groups (Attwood et al., 1998 (Attwood et al., , 1999a Tung et al., 1998) to generate inhibitors terminating in an electrophile such as a boronic acid (1) or phosphonate (2) (Llinas-Brunet et al., 1999b) . Two classes of electrophile-based inhibitors have been described, alphaketoamides (3) (Llinas-Brunet et al., 1999a; Tung et al., 1998) and hydrazinoureas (4) (Llinas-Brunet et al., 1999b) , which allow for prime-side binding by having an electrophile amenable for further derivativization ( Figure 2) . The C-terminal 5A-5B substrate cleavage product Asp-Asp-Ile-Val-Pro-Cys-OH has been reported to be a weak competitive inhibitor, IC 50 71 µM (Llinas-Brunet et al., 1998) and further modification has led to potent inhibitors for example, 5, IC 50 0.014 µM, which show a great degree of selectivity (>10 4 ) over other serine proteases such as human leukocyte elastase (HLE) (Llinas-Brunet et al., 1998 , 1999a . Potent product-based inhibitors have also been described starting from the 4A/4B cleavage product, Ac-Asp-Glu-Met-Glu-Glu-Cys-OH (K i 0.6 µM), for example 6, IC 50 0.0015 µM, but the activity against the isolated enzyme is affected significantly by the presence of 150 mM NaCl (Ingallinella et al., 1998) .
An extension of the substrate-based approach has been described wherein depsipeptide substrates, in which the scissile amide bond is replaced by an ester, are used to generate a pharmacophoric profile of the pockets on the nonprime side of the catalytic centre (Hart & Quibell, 1998) . This approach has only led to moderately potent inhibitors to date (for example 7, K i 5.4 µM) ( Figure 3) .
Inhibitors based on linked peptides have been described (Zhang et al., 1997) wherein residues from the 5A-5B cleavage site are linked to a portion of 4A, for example Glu-Asp-Val-Val-Cys-Cys-Acp-Acp-Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Val-Cys (9-21 are D-amino acids) IC 50 0.2 µM.
Structural information. The NS3 protease domain of the HCV BK strain has been crystallized uncomplexed (Love et al., 1996) , shown to contain a structural Zn atom and, unusually for a chymotrypsin-like protease, is inhibited by low micromolar concentrations of Cu 2+ (Stempniak et al., 1997) . Comparison of the protease 3D structure before and after NS4A binding (residues 21-34) (Love et al., 1998) suggests that the binding of NS4A improves the anchoring and orientation of the catalytic triad, provides new interactions with P′-side substrate residues, but has little effect on the binding site for non-P′-side substrate residues. This has been confirmed by two other X-ray structures of the NS3 protease domain complexed with a synthetic NS4A activator peptide, showing NS4A intercalating within a β sheet of the enzyme core (Kim et al., 1996; Yan et al., 1998) (Figure 4) .
A group has filed a patent on the use of compositions and crystals of a HCV protease in complex with the NS4A factor and also on methods of using the structural coordinates of HCV protease in complex with a synthetic NS4A peptide (Kim et al., 1998a) . There is one conference report of an X-ray study of the protease with a bound inhibitor (Love et al., 1998) .
Solution structures of the NS3 protease domain with product-based inhibitors Ac-Asp-Asp-Ile-Val-Hbp-Nva-OH (8) (LaPlante et al., 1999) and 9 (Barbato et al., 1999; Cicero et al., 1999) have been described ( Figure 5) .
The side chains of P1, P2 and P4 were shown to bind to pockets on the protease, while the P3 residue side chain appears to provide conformational rigidification ( Figure 5 ). The P1 carboxylate group is shown to interact with a Lys Non-substrate-based inhibitors. Evaluation of the inhibitory effects of 2,4,6-trihydroxy-3-nitro-benzamide derivatives against HCV protease and other serine proteases has been reported (Sudo et al., 1997 (Sudo et al., , 1998 . Using a reverse-phase HPLC assay (Sudo et al., 1996) , the two most potent compounds identified were RD3-4082 (10, IC 50 5.8 IC 50 22.2 µM) , the former substituted on the amide with a 14 carbon chain and the latter possessing a para-phenoxyphenyl group (Figure 6) .
These compounds were non-selective, inhibiting chymotrypsin (IC 50 values 1.16 µM and 4.47 µM for 10 and 11, respectively) or elastase (IC 50 values 18.76 µM and 90.4 µM). However, compound 12, although less active against the NS3 protease (IC 50 76.9 µM), was more selective against chymotrypsin (IC 50 >230 µM) and elastase (IC 50 >230 µM) (Figure 7) . Biochemical investigations revealed that 12 has a mixture of non-competitive and uncompetitive enzyme kinetics.
Thiazolidine derivatives have been identified as micromolar inhibitors, using a reverse-phase HPLC assay with an NS3/4A fusion protein and NS5A/5B substrate (Sudo et al., 1996 (Sudo et al., , 1997 . Compound , possessing a fused cinnamoyl moiety substituted with a long alkyl chain, was the most potent against the isolated enzyme with an IC 50 of 8.35 µM. Two other active examples are RD4-6205 (14, IC 50 14.5 µM) and RD4-6193 (15, IC 50 17.0 µM) ( Figure  8) .
The N-carboxy-methyl substituent in these compounds was found to be required for activity. Further studies against other serine proteases (chymotrypsin, trypsin, plasmin and elastase) showed these compounds to be nonselective with at least one other of these serine proteases inhibited with a lower IC 50 value than that for HCV pro-tease. Additionally, these thiazolidines were found to be cytotoxic to a range of cell lines at concentrations around that of their IC 50 values against HCV protease. Biochemical studies elucidated non-competitive enzyme kinetics.
Screening of a relatively small library using an ELISA assay has led to the identification of three compounds as potent inhibitors (Kakiuchi et al., 1998; Takeshita et al., 1997) , the thiazolidine compound 16 (3.2 µM) and two benzanilides 17 (6.5 µM) and 18 (6.2 µM) ( Figure 9 ). Interestingly, compound 16 has similar structural components to thiazolidines 13-15, although lacking the Ncarboxy methyl substituent. Unfortunately, 16 also inhibited factor Xa (47% at 10 µM) and trypsin (26.7% at 10 µM). Other serine proteases studied were chymotrypsin, kallikrein, plasmin and thrombin. Compounds 17 and 18 did not effectively inhibit these proteases. Preliminary kinetic studies were carried out and the mechanism of inhibition was found to be non-competitive.
Natural product screening is an often used source of potential enzyme inhibitors and there are two recent reports of its successful use for the discovery of HCV protease inhibitors. Isolated from the fermentation culture broth of Streptomyces sp., Sch 68631 (19), a phenanthrenequinone, possessed micromolar activity against HCV protease in a SDS-PAGE and autoradiography assay (Chu et al., 1996) (Figure 10) . In another example by the same authors, Sch 351633 (20), isolated from the fungus Penicillium griseofulvum, demonstrated micromolar activity in a scintillation proximity assay (SPA) (Chu et al., 1999) ( Figure 11 ). Nanomolar potency against the HCV NS3 protease enzyme has been achieved by the design of selective inhibitors based on the macromolecule eglin c. Eglin c, isolated from Hirudo medicinalis (leech), is a potent inhibitor of several serine proteases such as S. griseus proteases A and B, α-chymotrypsin, chymase and subtilisin (Qasim et al., 1997) . It is a 70 amino acid peptide lacking disulphides and with a remarkably high resistance not only to acid and thermal denaturation, but also to proteolysis (Seemuller et al., 1980) . These properties were the main reasons for choosing eglin c, rather than other macromolecular scaffolds. Additionally, eglin c is amenable to high levels of expression in the cytoplasm of Escherichia coli, and can withstand the experimental reducing conditions required for optimal protease activity. The tertiary structure of eglin c consists of a hydrophobic core and an exposed protease binding loop. This hydrophobic core contains a twisted four-stranded β-sheet and a short α-helix. The active sitebinding loop is held in its conformation by electrostatic and hydrogen bond interactions. Design of the NS3 inhibitors was based on reshaping the inhibitor active site-binding loop by site-directed mutagenesis (Martin et al., 1998) Figure 10 . A phenanthrenequinone HCV NS3 protease inhibitor most potent inhibitor developed had an IC 50 value of 60nM. Results obtained with these engineered inhibitors were consistent with earlier work (Heinz et al., 1992) . They demonstrate that the nature of the P1 side-chain is the most crucial factor for specificity and that the binding loop interface must be remodelled to maximize subsite interactions between P5 and P4′ to achieve a reasonable level of inhibition.
Macromolecular ligands of the NS3 protease domain have been engineered from phage-displayed repertoires of minibodies ('minimized' antibody-like proteins) and human pancreatic secretory trypsin inhibitor frameworks (Dimasi et al., 1997) . These were sampled using the recombinant NS3 protease domain as a ligate target molecule. Two protease inhibitors, one competitive and the other non-competitive, were identified with potencies in the low micromolar range, measured using an HPLC assay.
A genetic selection strategy has been employed in vitro to isolate, from a pool of completely random RNA, those RNA aptamers (nucleic acids that can bind target mole-cules with a high affinity and specificity) that could bind to NS3 (Urvil et al., 1997) . One aptamer inhibited the NS3 protease with a K i of 3 µM, exhibiting mixed competitive and non-competitive kinetics (Kumar et al., 1997) . These aptamers were also found to inhibit the NS3 helicase activity. The site of aptamer interactions in NS3 is not yet clear. 
